.jpeg)
ICRA report shows India pharma improving ESG metrics with higher renewable energy use, but facing challenges in energy intensity, hazardous waste, and governance gaps amid global compliance pressure.
AstraZeneca’s experimental breast cancer pill, camizestrant has received a regulatory boost in Europe, despite its trial design facing US regulatory pushback.
Reinforcing its position as a leading destination for advanced neurosciences care, Aster CMI Hospital has introduced two state-of-the-art robotic platforms for neurosurgery — Mazor X for spine surgery and ROSA for cranial and brain procedures.
The Indian Patent Office has refused to grant US pharmaceutical firm AbbVie a Hepatitis C patent for its combination therapy glecaprevir/pibrentasvir, marketed globally as Mavyret.
Calpol has long been a trusted name in Indian households, especially among parents looking for quick fever and pain relief for children. Now, Calpol has received one of the strongest forms of legal recognition in India after the Delhi High Court...
Reporting its fourth quarter results for FY 26, Zydus Wellness, reported a consolidated growth of 62.1% in Net Sales which stood at Rs. 14,761 million as compared to Rs. 9,106 million in the corresponding period of the previous year.
Cancer drug research continues to transform the global pharmaceutical industry as companies race to develop affordable and advanced oncology treatments. New FDA clearances reflect rapid growth in cancer drug research, especially in the breast...
Indoco Remedies Ltd. has announced that its manufacturing facility for solid oral dosage forms (Unit I) located at Baddi has received an EU GMP certificate from the Malta Medicines Authority, marking the company’s first step to European entry.
The Bajaj Group’s ?2,000 crore healthcare bet is officially underway in Pune, as the diversified conglomerate prepares to enter India’s healthcare sector with an ambitious long-term expansion strategy. The group plans to invest over ?2,000 crore...
Tata Group’s Arthritis Drug Deal with Vyome Holdings marks a major step in India’s growing biotech and pharmaceutical innovation space. The Arthritis Drug Deal involves Tata-backed Impetis Biosciences out-licensing two experimental drugs designed...
.jpg)
, CDSCO.jpg)